MILAN — Subcutaneous administration of anti-CD20 monoclonal antibody therapy offers ongoing clinical efficacy in the management of patients with relapsing and primary progressive multiple sclerosis ...

Reports on pregnancy outcomes following ofatumumab treatment can help health care professionals make better informed decisions when managing women of childbearing age living with MS. Maternal and ...

Please provide your email address to receive an email when new articles are posted on . DENVER — Early initiation of treatment with ofatumumab showed sustained benefit to those with treatment-naïve ...

Ofatumumab is more effective than teriflunomide for relapsing multiple sclerosis across subgroups. HealthDay News — For patients with relapsing multiple sclerosis (RMS), ofatumumab is more effective ...

Copenhagen, Denmark; March 30, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted Novartis marketing authorization for the use of Kesimpta® (ofatumumab) in ...

Multiple sclerosis (MS) patients treated with ofatumumab (Kesimpta) in an open-label extension study had non-serious cases of COVID-19 and recovered relatively quickly, researchers reported. Of 139 ...

The monoclonal antibody ofatumumab appears to be more effective in achieving a disease-free state in relapsing-remitting multiple sclerosis (RRMS) than the immunomodulatory drug teriflunomide, across ...

Please provide your email address to receive an email when new articles are posted on . Two studies included 1,367 patients with MS who were given continuous Kesimpta or switched to Kesimpta. Kesimpta ...

MINNEAPOLIS – Certain medications for multiple sclerosis (MS) called monoclonal antibodies, taken while breastfeeding, may not affect the development of a child during the first three years of life, ...

COPENHAGEN, Denmark, Sept. 16, 2010 (GLOBE NEWSWIRE) -- Summary: GlaxoSmithKline and Genmab A/S announce plans to refocus the development program of ofatumumab in autoimmune indications.

Two weeks after a third shot, many MS patients on anti-CD20 drugs and sphingosine-1-phosphate (S1P) receptor modulators still had significantly reduced total spike and receptor-binding domain (RBD) ...